Instil Bio to Begin Phase II Trial of TIL Therapy for Advanced Melanoma
Source: Precision Oncology, September 2021
NEW YORK – Instil Bio said on Monday that following the US Food and Drug Administration’s clearance of its investigational new drug application for ITIL-168, it will begin a Phase II clinical trial evaluating the autologous tumor-infiltrating lymphocyte, or TIL, therapy for advanced melanoma patients.
